VANECK VECTORS ETF TR's ticker is GDX and the CUSIP is 92189F106. A total of 733 filers reported holding VANECK VECTORS ETF TR in Q2 2023. The put-call ratio across all filers is 0.48 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,080 | +315.4% | 40,141 | +399.0% | 0.01% | +250.0% |
| Q1 2023 | $260 | -100.0% | 8,045 | -65.5% | 0.00% | -71.4% |
| Q2 2022 | $638,000 | +110.6% | 23,319 | +122.4% | 0.01% | +250.0% |
| Q3 2021 | $303,000 | -92.9% | 10,483 | -91.7% | 0.00% | -94.3% |
| Q2 2021 | $4,292,000 | +337.1% | 126,316 | +318.0% | 0.07% | +337.5% |
| Q1 2021 | $982,000 | -82.3% | 30,220 | -80.4% | 0.02% | -75.8% |
| Q4 2020 | $5,562,000 | +1088.5% | 154,418 | +1109.4% | 0.07% | +450.0% |
| Q2 2020 | $468,000 | -51.6% | 12,768 | -69.5% | 0.01% | -40.0% |
| Q1 2020 | $966,000 | +341.1% | 41,918 | +460.9% | 0.02% | +150.0% |
| Q4 2019 | $219,000 | -47.2% | 7,473 | -62.0% | 0.01% | -65.2% |
| Q4 2018 | $415,000 | -80.8% | 19,689 | -83.1% | 0.02% | -78.1% |
| Q3 2018 | $2,158,000 | +72.5% | 116,531 | +107.9% | 0.10% | +75.0% |
| Q2 2018 | $1,251,000 | -41.8% | 56,056 | -42.7% | 0.06% | -39.4% |
| Q1 2018 | $2,151,000 | – | 97,855 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 738,500 | $20,220,000 | 66.82% |
| Baymount Management LP | 145,000 | $3,970,000 | 28.08% |
| New Harbor Financial Group, LLC | 1,371,341 | $37,547,000 | 18.51% |
| New Harbor Financial Group, LLC | 1,291,700 | $35,366,000 | 17.44% |
| MKP Capital Management, L.L.C. | 1,500,000 | $41,070,000 | 13.74% |
| Windmill Hill Asset Management Ltd | 844,600 | $23,125,000 | 11.94% |
| Hollow Brook Wealth Management LLC | 768,567 | $21,043,000 | 11.57% |
| Grand Central Investment Group | 261,915 | $7,171,000 | 10.33% |
| Point72 Europe (London) LLP | 1,467,000 | $40,166,000 | 8.50% |
| Slate Path Capital LP | 4,600,000 | $125,948,000 | 7.87% |